Tlr8 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| TLR8 Gene |
|---|
| Gene Symbol | TLR8 |
| Full Name | Toll-Like Receptor 8 |
| Chromosomal Location | Xp22.2 |
| NCBI Gene ID | 51311 |
| OMIM | 300366 |
| Ensembl ID | ENSG00000101916 |
| UniProt | Q9NYK5 |
| Protein Class | Pattern Recognition Receptor (TLR family) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Rheumatoid Arthritis, Viral Infections, Systemic Lupus Erythematosus |
TLR8 (Toll-Like Receptor 8) encodes an endosomal pattern recognition receptor that plays crucial roles in antiviral immunity and autoimmune responses. Located on the X chromosome at Xp22.2, TLR8 is primarily expressed in myeloid cells and recognizes single-stranded RNA (ssRNA) from viruses as well as synthetic antiviral compounds. Unlike TLR7, which is located on the X chromosome and escapes X-inactivation in females, TLR8 undergoes complete X-inactivation, leading to expression from only one allele in female cells. TLR8 has emerged as an important player in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, where it contributes to neuroinflammation through recognition of endogenous nucleic acids released from dying neurons.
TLR8 belongs to the TLR7/8/9 subfamily of endosomal TLRs that specialize in nucleic acid recognition. These receptors are located primarily in endoplasmic reticulum-derived endosomes, where they survey for incoming pathogens. TLR8 forms functional homodimers upon ligand binding, similar to TLR7, but has distinct ligand specificity and expression patterns.
¶ Extracellular Domain
The TLR8 protein contains several distinctive structural features:
- Leucine-rich repeat (LRR) domain: Consists of 25 LRR motifs that form the ligand-binding region
- Z-loop: A unique insertion between LRR14 and LRR15 that undergoes proteolytic cleavage and is required for ligand recognition
- Ligand-binding pocket: Recognizes guanosine- and uridine-rich ssRNA sequences
- Glycosylation: Multiple N-linked glycosylation sites affect folding and trafficking
¶ Transmembrane and Intracellular Domains
- Single transmembrane helix: Contains a sorting motif for endosomal localization
- TIR domain: Intracellular signaling domain approximately 200 amino acids
- BB loop: Critical for adaptor protein interactions
Crystal structures of TLR8 have revealed:
- Dimerization mechanism: Two TLR8 monomers form a "m-shaped" dimer upon ligand binding
- Ligand recognition: Small molecules and ssRNA bind in the central dimerization interface
- Species differences: Human TLR8 has different agonist sensitivity compared to mouse TLR8
TLR8's primary function is detection of viral ssRNA:
- Endosomal localization: TLR8 is retained in the endoplasmic reticulum and traffics to endosomes upon activation
- Ligand delivery: Viral RNA is delivered to endosomes through endocytosis
- Proteolytic processing: Endosomal proteases cleave TLR8, enabling ligand binding
- Dimerization: Two cleaved TLR8 molecules dimerize with bound ligand
- Signaling initiation: TIR domains dimerize and recruit adaptor proteins
TLR8 activates innate immune signaling through multiple pathways:
| Pathway |
Key Components |
Outcome |
| MyD88-dependent |
MyD88 → IRAK4/1 → TRAF6 |
NF-κB, AP-1 activation |
| NF-κB pathway |
TAK1 → IKK complex |
Proinflammatory gene expression |
| MAPK pathway |
ERK, JNK, p38 activation |
Cytokine production, cell activation |
| IRF pathway |
IRF7 activation |
Type I interferon response |
TLR8 activation induces various immune cell responses:
- Monocyte activation: Proinflammatory cytokine production (TNF-α, IL-6, IL-12)
- Neutrophil activation: Enhanced survival and antimicrobial activity
- Dendritic cell maturation: Increased co-stimulatory molecule expression
- B cell activation: Enhanced antibody responses
- T cell modulation: Can enhance or inhibit T cell responses
TLR8 shows distinctive expression in immune cells:
- Monocytes/macrophages: High expression, primary responders
- Neutrophils: High expression, rapid responses
- Myeloid dendritic cells: Moderate to high expression
- Plasmacytoid dendritic cells: Low expression (TLR7 dominates)
- B cells: Low to moderate expression
- Highest expression: Peripheral blood leukocytes, spleen
- High expression: Lung, liver
- Moderate expression: Heart, placenta
- Brain expression: Primarily microglia and infiltrating immune cells
Within the central nervous system:
- Microglia: Primary TLR8-expressing cells in the brain
- Infiltrating monocytes: Contribute to neuroinflammation
- Neurons: Very low or absent expression under normal conditions
- Astrocytes: Limited expression
TLR8 has several connections to Alzheimer's disease pathogenesis:
- Endogenous ligand recognition: May detect extracellular RNA from dying neurons
- Microglial activation: TLR8 on microglia contributes to chronic neuroinflammation
- Amyloid interaction: May modulate microglial responses to amyloid-beta plaques
- Autoimmune component: May recognize endogenous "self-RNA" in autoimmune contexts
- Sex differences: X-chromosome location may contribute to sex-biased disease prevalence
TLR8 plays a role in Parkinson's disease through:
- Nucleic acid release: Dying dopaminergic neurons release nucleic acids
- Microglial TLR8: Recognizes extracellular RNA, triggering inflammation
- Alpha-synuclein interaction: May recognize RNA bound to alpha-synuclein
- Inflammatory cascade: Contributes to chronic neuroinflammation in substantia nigra
- Sex-specific effects: X-chromosome location may explain some sex differences in PD
- Synovial expression: TLR8 is overexpressed in rheumatoid arthritis synovium
- Joint inflammation: Contributes to inflammatory cascade in joints
- Therapeutic target: TLR8 antagonists being investigated
- Autoantibody generation: TLR8 activation may contribute to autoimmunity
- Endogenous ligand recognition: May recognize self-RNA in immune complexes
- Type I interferon: Contributes to the interferon signature in SLE
TLR8 contributes to neuroinflammation through:
- Microglial activation: Direct activation by extracellular RNA
- Cytokine production: TNF-α, IL-1β, IL-6, and other proinflammatory mediators
- Nitric oxide production: Induction of inducible nitric oxide synthase
- Reactive oxygen species: NADPH oxidase activation
- Blood-brain barrier disruption: Matrix metalloproteinase induction
- Neuronal toxicity: Direct and indirect effects on neuron viability
¶ Endogenous Ligands
TLR8 can be activated by endogenous ligands:
- Extracellular RNA: Released from dying neurons
- RNA-containing immune complexes: From autoimmune conditions
- MicroRNA: Some studies suggest miRNA can activate TLR8
- Altered self-RNA: Modified or mislocalized cellular RNA
This endogenous activation may contribute to sterile inflammation in neurodegeneration.
Several TLR8 antagonists are under development:
| Compound |
Mechanism |
Development Stage |
| CU-CPT8m |
Small molecule antagonist |
Preclinical |
| C909 |
TLR8-specific antagonist |
Research |
| Imidazoquinoline derivatives |
Ligand competitors |
Research |
| Oligonucleotide-based |
Decoy TLR8 ligands |
Research |
- Natural compounds: Some flavonoids and terpenoids inhibit TLR8
- Broad-spectrum TLR inhibitors: Target multiple TLRs including TLR8
- ** downstream blockers**: Target signaling molecules (TAK1, IKK)
- Immune suppression risk: Blocking TLR8 may impair antiviral immunity
- Compartmentalization: Endosomal vs. cell surface TLR8 may differ
- Redundancy: Other TLRs may compensate if TLR8 is blocked
- Sex-specific effects: Need to consider X-inactivation in females
Genetic variants in TLR8 affect function:
- 1-bp deletion (GT): Common variant affecting function in some populations
- Missense variants: Various amino acid changes with functional consequences
- Expression variants: Affect expression levels
These variants may influence susceptibility to infections and autoimmune diseases.
- X-inactivation: TLR8 undergoes complete X-inactivation
- Female mosaicism: Females express only one TLR8 allele per cell
- Sex differences: May contribute to differences in immune responses between sexes
Current areas of active investigation include:
- Selective antagonists: Developing TLR8-specific inhibitors with better profiles
- Structural studies: Understanding TLR8 activation at atomic resolution
- Biomarkers: TLR8 expression as a disease biomarker
- Combination therapies: TLR8 inhibitors with other immunomodulators
- Sex-specific approaches: Considering X-inactivation in therapy design
- Jurk et al., Human TLR7 or TLR8 confer responsiveness to R-848 (2002) — Original characterization of TLR8 function
- Bsibsi et al., Broad expression of TLRs in human CNS (2002) — TLR expression in brain
- Gorden et al., TLR7 and TLR8 have distinct ligand recognition (2006) — Structural basis for ligand specificity
- Heil et al., Species-specific recognition of ssRNA by TLR7 and TLR8 (2004) — Species differences
- Tanji et al., TLR8 structure reveals activation mechanism (2013) — Crystal structure of TLR8
The study of Tlr8 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Jurk et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 (2002)
- Bsibsi et al., Broad expression of Toll-like receptors in the human central nervous system (2002)
- Gorden et al., TLR7 and TLR8 have distinct ligand recognition (2006)
- Heil et al., Species-specific recognition of ssRNA by TLR7 and TLR8 (2004)
- Tanji et al., Structure of human TLR8 (2013)
- Kawai and Akira, TLR signaling (2007)
- Heneka et al., Neuroinflammation in Alzheimer's disease (2015)
- Glass et al., Microglial identity and inflammatory responses in Alzheimer's disease (2010)